OtherGastrointestinal, Hepatic, Pulmonary, and Renal
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler, Tobias Chapman, Li-Li Yang, Tim Wyant, Robert Egan and Eric R. Fedyk
Journal of Pharmacology and Experimental Therapeutics June 9, 2009, DOI: https://doi.org/10.1124/jpet.109.153973
Dulce Soler
Tobias Chapman
Li-Li Yang
Tim Wyant
Robert Egan
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
OtherGastrointestinal, Hepatic, Pulmonary, and Renal
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler, Tobias Chapman, Li-Li Yang, Tim Wyant, Robert Egan and Eric R. Fedyk
Journal of Pharmacology and Experimental Therapeutics June 9, 2009, DOI: https://doi.org/10.1124/jpet.109.153973
OtherGastrointestinal, Hepatic, Pulmonary, and Renal
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-α4β7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler, Tobias Chapman, Li-Li Yang, Tim Wyant, Robert Egan and Eric R. Fedyk
Journal of Pharmacology and Experimental Therapeutics June 9, 2009, DOI: https://doi.org/10.1124/jpet.109.153973
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement